Publications by authors named "S Montes-Moreno"
Is Bone Marrow Trephine Biopsy Necessary in Multiple Myeloma Patients at Diagnosis?
Clin Lymphoma Myeloma Leuk
December 2024
Multiple myeloma (MM) diagnosis requires ≥10% plasma cell (PC) infiltration in the bone marrow (BM), detected by bone marrow aspiration (BMA) or biopsy (BMB). We evaluated the concordance of these 2 techniques in 189 patients. In 43 cases (23%), the techniques were discordant, 10 due to poor sample quality.
View Article and Find Full Text PDFPlasma cell neoplasia and POEMS syndrome patients may present Castleman disease (CD)-type features in lymph nodes. Our aim was to better characterize the histopathological patterns found in plasma cell neoplasia associated CD and to improve the detection of clonal plasma cell populations in the lymph node biopsies of these patients. Lymph node and bone marrow samples from six cases with plasma cell neoplasia associated CD, including POEMS syndrome and multiple myeloma were analyzed.
View Article and Find Full Text PDFIntramuscular hemangioma of the infraspinatus muscle: a rare presentation.
Case Reports Plast Surg Hand Surg
August 2024
Intramuscular hemangiomas (IMH) are extremely rare, accounting for 0.8% of all hemangiomas. IMH must be included in the differential diagnosis of soft tissue masses, and unexplained muscular pain.
View Article and Find Full Text PDFArticle Synopsis
- Deficient DNA mismatch repair (dMMR) serves as a biomarker indicating a better response to PD-1 blockade immunotherapy in solid tumors, including diffuse large B-cell lymphoma (DLBCL).
- In a study involving a large cohort of DLBCL patients, genetic dMMR was found infrequently and linked to a more favorable immune microenvironment but did not show a strong prognostic impact.
- Additionally, while phenotypic dMMR was also rare, its presence correlated with increased T cell activity, suggesting that PD-1 T cells may selectively target tumor cell subsets with dMMR, which has implications for the efficacy of immunotherapy in DLBCL.
Ibrutinib in Combination with R-GemOx in Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma of Nongerminal Center B-cell-like Type: Phase II Clinical Trial of the Spanish GELTAMO Group.
Clin Cancer Res
September 2024
Purpose: This phase II clinical trial evaluated the combination of ibrutinib with rituximab, gemcitabine, and oxaliplatin (R-GemOx) in patients with nongerminal center B-cell-like (non-GCB) diffuse large B-cell lymphoma (DLBCL).
Patients And Methods: The IBDCL trial (NCT02692248) included patients with histologic diagnosis of non-GCB DLBCL with relapsed or refractory disease and non-candidates for stem-cell transplantation. Patients received an induction treatment consisting of six or eight cycles of R-GemOx at standard doses every 2 weeks, in combination with ibrutinib (560 mg daily), followed by a maintenance treatment with ibrutinib for a maximum of 2 years.